Drug Profile
Altinicline
Alternative Names: SIB-1508; SIB-1508YLatest Information Update: 30 Nov 2006
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antiparkinsonians
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 21 Jun 2000 A study has been added to the adverse events and Parkinson's Disease and Movement Disorders therapeutic trials sections
- 16 Dec 1999 SIBIA Neurosciences has been acquired by, and integrated into, Merck & Co.
- 10 Nov 1999 A preclinical study has been added to the Parkinson's Disease and Movement Disorders pharmacodynamics section